139 related articles for article (PubMed ID: 24509338)
1. Selected parameters of hemostasis in patients with myeloproliferative neoplasms.
Gadomska G; Rość D; Stankowska K; Boinska J; Ruszkowska-Ciastek B; Wieczór R
Blood Coagul Fibrinolysis; 2014 Jul; 25(5):464-70. PubMed ID: 24509338
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
3. [Hemostatic disturbances in chronic myeloid leukemia].
Rość D; Kremplewska-Nalezyta E; Gadomska G; Bielis L
Wiad Lek; 2007; 60(3-4):138-42. PubMed ID: 17726865
[TBL] [Abstract][Full Text] [Related]
4. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
5. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
6. [Changes of blood coagulative and fibrinolytic system and function of pulmonary vascular endothelium after therapy in patients with acute pulmonary thromboembolism].
Pang BS; Wang C; Lu Y; Yang YH; Xing GH; Mao YL; Huang XX; Zhai ZG
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3074-8. PubMed ID: 18261355
[TBL] [Abstract][Full Text] [Related]
7. [Haemostatic disturbances in essential thrombocythosis].
Rośc D; Gadomska G; Kremplewska-Nalezyta E; Bielis L
Przegl Lek; 2007; 64(3):121-3. PubMed ID: 17941461
[TBL] [Abstract][Full Text] [Related]
8. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].
Zalewska-Rydzkowska D; Rość D; Ponikowska I; Michalski A; Graczykowska-Koczorowska A; Rydzkowski M
Pol Merkur Lekarski; 2001 Nov; 11(65):414-7. PubMed ID: 11852811
[TBL] [Abstract][Full Text] [Related]
9. Dkk3 levels in patients with myeloproliferative neoplasms.
Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
[TBL] [Abstract][Full Text] [Related]
10. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
[TBL] [Abstract][Full Text] [Related]
11. Profile of blood coagulation and fibrinolysis in chronic myeloproliferative disorders.
Takahashi H; Hattori A; Shibata A
Tohoku J Exp Med; 1982 Sep; 138(1):71-80. PubMed ID: 6959382
[TBL] [Abstract][Full Text] [Related]
12. Hemostasis during normal pregnancy and puerperium.
Hellgren M
Semin Thromb Hemost; 2003 Apr; 29(2):125-30. PubMed ID: 12709915
[TBL] [Abstract][Full Text] [Related]
13. Tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in patients with symptomatic lower extremity artery disease.
Wieczór R; Wieczór AM; Rość D
Minerva Cardiol Angiol; 2021 Apr; 69(2):161-171. PubMed ID: 32643893
[TBL] [Abstract][Full Text] [Related]
14. PAI-1 and α2-AP in patients with morbid obesity.
Michalska M; Iwan-Ziętek I; Gniłka W; Dąbrowiecki S; Góralczyk B; Góralczyk K; Drela E; Rość D
Adv Clin Exp Med; 2013; 22(6):801-7. PubMed ID: 24431308
[TBL] [Abstract][Full Text] [Related]
15. Hemostatic alterations associated with supraceliac aortic cross-clamping.
Anagnostopoulos PV; Shepard AD; Pipinos II; Raman SB; Chaudhry PA; Mishima T; Morita H; Suzuki G
J Vasc Surg; 2002 Jan; 35(1):100-8. PubMed ID: 11802139
[TBL] [Abstract][Full Text] [Related]
16. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
[TBL] [Abstract][Full Text] [Related]
17. [Abnormal blood coagulation and fibrinolysis in chronic myeloproliferative disorders].
Mamiya S; Itoh T; Endo Y; Miura AB
Rinsho Ketsueki; 1991 May; 32(5):527-36. PubMed ID: 1870270
[TBL] [Abstract][Full Text] [Related]
18. [Activation of fibrynolysis in children with chronic B or C hepatitis].
Michalska K; Szaflarska-Popławska A; Dymek G; Kotschy M
Pol Merkur Lekarski; 2004 Oct; 17(100):316-20. PubMed ID: 15690691
[TBL] [Abstract][Full Text] [Related]
19. [Plasminogenesis in blood of patients with chronic myeloproliferative syndromes].
Rość D; Kremplewska-Nalezyta E; Gadomska G; Drewniak W; Koczubik W
Pol Arch Med Wewn; 2006 Jan; 115(1):23-8. PubMed ID: 17278781
[TBL] [Abstract][Full Text] [Related]
20. The coagulation and fibrinolytic responses of baboons after in vivo thrombin generation--effect of interleukin 6.
Kruithof EK; Mestries JC; Gascon MP; Ythier A
Thromb Haemost; 1997 May; 77(5):905-10. PubMed ID: 9184401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
